In summary, we report GZD824 as a pan‐FGFR inhibitor which inhibits the signaling pathways of FGFR1 kinases and suppresses the proliferation of cancer cells harboring overexpression or mutant activation of FGFR1 in vitro and in vivo. Here, FGFR1 is linked to cancer.